androgen deprivation therapy
androgen suppression therapy , ADT (skrót)

In total, just over half of the men were taking androgen deprivation therapy.

There are two methods of androgen deprivation therapy based on drugs.

All of the men had received androgen deprivation therapy as a treatment for their cancers.

Overall, 1,015 patients used androgen deprivation therapy for an average of 4.1 months, the report indicates.

Might androgen deprivation therapy raise the risk for colorectal cancer?

It has been used as a means of androgen deprivation therapy to treat prostate cancer.

On further analysis, the researchers found that androgen deprivation therapy increased the risk of death from cardiovascular disease by 2.6-fold.

"If you need androgen deprivation therapy for your prostate cancer, go ahead and have it.

Men with prostate cancer who choose androgen deprivation therapy.

For example, androgen deprivation therapy using antiandrogens is important in treating prostate cancer.

The treatment, known as androgen deprivation therapy, lowers the risk of death among men with advanced, aggressive prostate cancer.

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

Plus, the short course of androgen deprivation therapy does not increase the risk of death from cardiovascular disease, which had been a concern.

Additional studies need to be done to confirm the associations among androgen deprivation therapy, cardiovascular disease, and mortality.

"Previous studies have shown androgen deprivation therapy to be associated with an increased risk of diabetes and cardiovascular disease.

"This message should be reassuring for the vast majority of patients considering androgen deprivation therapy," Nguyen said in a statement.

The studies included about 2,500 men that were treated with androgen deprivation therapy over anywhere from three months to indefinitely, and 2,300 that weren't.

Prostate cancer patients may undergo bone-damaging, long-term androgen deprivation therapy to keep male hormones low.

Individuals with prostate cancer who are treated with androgen deprivation therapy may experience gynecomastia.

Furthermore, adding androgen deprivation therapy to radiotherapy did not increase the risk of death from cardiovascular disease, the findings indicate.

"Methods of reducing the potentially negative side effects of androgen deprivation therapy should be explored," he added.

"Treatment with androgen deprivation therapy can be beneficial in patients with unfavorable prostate cancer.

A program has been developed for patients and their partner to recognize and manage the more burdensome side effects of androgen deprivation therapy.

Androgen deprivation therapy is a type of hormone therapy, usually given to men with advanced or difficult to treat cancers.

Androgen deprivation therapy (ADT), also called androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer.

Because weight training (resistance exercise) has been shown to help healthy men build muscle, reduce fat, and improve mood, the researchers surmised it could have similar benefits for men on androgen suppression therapy.

The finding will be important because many men are now being treated with new, highly potent androgen suppression therapy, which the researchers said will significantly increase the risk of future development of neuroendocrine tumors.

Drugs that suppress the production of testosterone – known as androgen suppression therapy (AST) – are a key treatment for advanced prostate cancer, with evidence showing they work well to combat the disease.

Androgen is the fuel that feeds adenocarcinoma prostate cancers -- the most common kind of prostate cancer -- and androgen suppression therapy effectively destroys cancer cells that depend on this hormone, Rubin explained.

Addition of androgen suppression therapy to EBRT may benefit men who are at an elevated risk of disease recurrence and death from prostate cancer (RTOG-9202 [NCT00767286]).

Also, the evidence was judged insufficient to determine whether men newly diagnosed with asymptomatic metastatic disease should have immediate androgen suppression therapy or should have therapy deferred until they have clinical signs or symptoms of progression.

Hormone therapy for prostate cancer-also called androgen suppression therapy or androgen deprivation therapy-can block the production and use of androgens (3).